Savara Inc (SVRA): Long-Term Debt
$29.91M
As of 2025-12-31
$30.11M
As of 2026-06-30
+4.7%
3-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $29.91M | +12.4% | 2026-03-13, Balance as of period end |
| 2024-12-31 | $26.62M | +1.0% | 2025-03-27, Balance as of period end |
| 2023-12-31 | $26.35M | +1.0% | 2024-03-07, Balance as of period end |
| 2022-12-31 | $26.08M | +1.6% | 2023-03-30, Balance as of period end |
| 2021-12-31 | $25.66M | n/a | 2022-03-30, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Savara Inc (SVRA) | 2025-12-31 | $29.91M | +12.4% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $209.09M | +3.8% |
| Verastem, Inc. (VSTM) | 2024-12-31 | $40.72M | +1.6% |
| Perspective Therapeutics, Inc. (CATX) | 2025-12-31 | $1.62M | -3.1% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $130.44M | +4.6% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2024-12-31 | $8.65M | -21.4% |
| Altimmune, Inc. (ALT) | 2025-12-31 | $34.29M | n/a |
| Evolus, Inc. (EOLS) | 2025-12-31 | $146.10M | +20.2% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $61.93M | +4.1% |
Compare SVRA, PHAT, VSTM, CATX side by side · Screen every company in Pharmaceutical Preparations ↗